Literature DB >> 23418935

Clinical significance of variations in levels of Epstein-Barr Virus (EBV) antigen and adaptive immune response during chronic active EBV infection in children.

Yan Xing1, Hong Mei Song, Min Wei, Yu Liu, Yu Hua Zhang, Li Gao.   

Abstract

Pediatric patients were recruited to analyze differences in Epstein-Barr virus (EBV) copy numbers and adaptive immune reactions in children with chronic active vs acute EBV infection (CAEBVI vs AEBVI), as well as to examine the relationship between these parameters and the pathogenesis of CAEBVI. Fluorescent qPCR was used to assess EBV-DNA levels, while ELISA, antibody affinity, flow cytometry, and heterophil agglutination (HA) assays were used to evaluate patient EBV-adaptive humoral and cellular immunity. Lastly, ELISPOT was employed to assess interferon (IFN)-γ secretory functions of EBV-specific cytotoxic T-lymphocytes (CTL) as a marker of subject EBV-specific adaptive cellular immunity. The results indicated that, compared with AEBVI patients or normal children, there was a dramatic elevation in viral copy levels, viral capsid antigen (VCA)-IgA, early antigen (EA)-IgA, and EA-IgG, but a lack of EBV nuclear antigen (EBNA)-IgG and a negative HA in CAEBVI patients (p < 0.01). These subjects also had decreased CD4(+), CD8(+) (naïve), CD8(+)CD38(+), and effective memory T-lymphocyte levels compared with AEBVI patients (p < 0.01), and decreased EBV-specific CTL function compared with normal children (p < 0.01). These results suggest that there is a disturbance in EBV antigen availability and in both the adaptive humoral and cellular immune responses in patients with CAEBVI, and that these outcomes may be associated with the chronic active re-infection process itself associated with CAEBVI.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23418935     DOI: 10.3109/1547691X.2012.758199

Source DB:  PubMed          Journal:  J Immunotoxicol        ISSN: 1547-691X            Impact factor:   3.000


  5 in total

1.  Expression of EBV antibody EA-IgA, Rta-IgG and VCA-IgA and SA in serum and the implication of combined assay in nasopharyngeal carcinoma diagnosis.

Authors:  Cui Xia; Kang Zhu; Guoxi Zheng
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

2.  How I treat T-cell chronic active Epstein-Barr virus disease.

Authors:  Catherine M Bollard; Jeffrey I Cohen
Journal:  Blood       Date:  2018-04-30       Impact factor: 22.113

3.  Serological Assessment of 18 Pathogens and Risk of AIDS-Associated Non-Hodgkin Lymphoma.

Authors:  Gordana Halec; Tim Waterboer; Nicole Brenner; Julia Butt; W David Hardy; Gypsyamber DʼSouza; Steven Wolinsky; Bernard J Macatangay; Michael Pawlita; Roger Detels; Otoniel Martínez-Maza; Shehnaz K Hussain
Journal:  J Acquir Immune Defic Syndr       Date:  2019-03-01       Impact factor: 3.771

4.  Expression of Serum Sialic Acid, Early Antigen-IgA, and Viral Capsid Antigen-IgA in Nasopharynx Cancer Patients: The Diagnostic Implication of Combined Assays.

Authors:  Yuning Sun; Caibo Sun; Endong Zhang
Journal:  Med Sci Monit       Date:  2015-12-28

Review 5.  Chronic Active Epstein-Barr Virus Disease.

Authors:  Hiroshi Kimura; Jeffrey I Cohen
Journal:  Front Immunol       Date:  2017-12-22       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.